drugset / Trial / NCT02956044

Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin

NCT02956044

Phase 1 Completed 54 enrolled Theracos
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to examine the drug-drug interaction in your body when given the study drug, bexagliflozin, with three commonly used ant-diabetic medications, metformin, glimepiride or sitagliptin. The study will also evaluate how safe the study drug is and how well the study drug is tolerated when taken with metformin, glimepiride or sitagliptin.

Timeline

Start
2016-11
Primary completion
2017-03
Completion
2017-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bexagliflozin Small molecule 20 mg
Comparator Glimepiride Small molecule 2 mg Oral
Comparator Glimepiride Small molecule 4 mg Oral
Comparator Metformin Small molecule 1000 mg Oral
Comparator Sitagliptin Small molecule 100 mg Oral